Take Homes in CAR T-cell Therapy

Take Homes in CAR T-cell Therapy

Source:

Chavez, RG et al. Abstract 1200. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.

Disclosures: Locke reports holding a scientific advisory role for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and acting as consultant with grant options for Cellular Biomedicine Group Inc.
December 09, 2020
1 min watch
Save

VIDEO: Ibrutinib before apheresis requires further study, may improve CAR-T manufacturing

Source:

Chavez, RG et al. Abstract 1200. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.

Disclosures: Locke reports holding a scientific advisory role for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and acting as consultant with grant options for Cellular Biomedicine Group Inc.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

New data suggest ibrutinib may be able to improve CAR T-cell production when administered before apheresis, according to a presentation at the ASH Annual Meeting and Exposition.

“We found that early use of ibrutinib as a lead into apheresis actually led to a phenotype of the CAR T-cell product that was more sort of central memory and more stem-like product that expanded better within the patients. It suggests ... the use of ibrutinib in DLBCL lymphoma patients can improve the function of CAR T-cells if given before apheresis,” Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, said in a Healio interview.